Mydecine Innovations Group Appoints Josephine Wu to Board of Directors
Mydecine Innovations Group Appoints Josephine Wu to Board of Directors Mydecine Innovations Group an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced the appointment of Josephine Wu, Founder and CIO at Aionious Management, Ltd., to the Company’s Board of Directors. Josh Bartch, Chairman and CEO of Mydecine, stated, “The Board of Directors welcomes Ms. Josephine Wu … Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a...
Source: investingnews.com